FY2024 EPS Estimates for uniQure Lowered by Leerink Partnrs

uniQure (NASDAQ:QURE) – Equities researchers at Leerink Partnrs decreased their FY2024 earnings estimates for uniQure in a report released on Tuesday, December 10th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings per share of ($2.39) for the year, down from their previous forecast of ($2.28). The consensus estimate for uniQure’s current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for uniQure’s Q4 2024 earnings at $1.14 EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.53) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($1.08) EPS.

Several other equities analysts have also recently commented on QURE. Leerink Partners increased their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $20.00 to $52.00 in a research note on Tuesday. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday. Finally, Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $32.14.

uniQure Stock Performance

uniQure stock opened at $15.40 on Friday. The stock has a market cap of $750.60 million, a P/E ratio of -3.10 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a 50 day moving average of $6.85 and a 200-day moving average of $6.28. uniQure has a 52 week low of $3.73 and a 52 week high of $17.39.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC increased its holdings in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Geode Capital Management LLC increased its holdings in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after purchasing an additional 6,362 shares during the period. American Century Companies Inc. increased its holdings in shares of uniQure by 14.6% during the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the period. Finally, RTW Investments LP acquired a new position in shares of uniQure during the third quarter valued at $49,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.